Remove Gene Expression Remove In-Vivo Remove Research Remove Scientist
article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Bachem has spent time studying and researching this reaction, along with the side-reactions that happen during the coupling stage. Currently, only a small number of CPP-based oligonucleotide delivery examples have been reported for in vivo application. However, this method does come with one major drawback.

article thumbnail

Fibrosis research: Advances and challenges 

Drug Discovery World

DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FAIR Game: making data work harder in the race to market 

Drug Discovery World

For pharma and biotech companies – whether working on small or large molecule drugs, or cell and gene therapies – this means empowering scientists with better and faster data management approaches, best practices, and leading technologies so they can pinpoint new molecules and formulations and modify existing ones more easily and quickly.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields, providing a versatile tool for precise and efficient genome editing.

DNA 98
article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

Even as methods in DNA synthesis continue to advance, scientists’ reliance on third-party companies for synthesising DNA creates a bottleneck, impeding research timelines. . “If If you want to order gene-length sequences, rather than short oligos for PCR, the waiting times are around two or three weeks at least.

DNA 98
article thumbnail

The use of base editing in stem-cell based therapies

Drug Discovery World

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Adult fibroblasts were cultured in a cocktail of transcription factors to reactivate embryonic gene expression patterns 2.